𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular analysis of acid ceramidase deficiency in patients with Farber disease

✍ Scribed by Julia Bär; Thomas Linke; Klaus Ferlinz; Ulrich Neumann; Edward H. Schuchman; Konrad Sandhoff


Book ID
102262170
Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
319 KB
Volume
17
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis


Farber disease is a rare, autosomal recessively inherited sphingolipid storage disorder due to the deficient activity of lysosomal acid ceramidase, leading to the accumulation of ceramide in cells and tissues. Here we report the identification of six novel mutations in the acid ceramidase gene causing Farber disease: three point mutations resulting in single amino acid substitutions, one intronic splice site mutation resulting in exon skipping, and two point mutations also leading to occasional or complete exon skipping. Of interest, these latter two mutations occurred in adjacent nucleotides and led to abnormal splicing of the same exon. Expression of the mutated acid ceramidase cDNAs in COS-1 cells and subsequent determination of acid ceramidase residual enzyme activity demonstrated that each of these mutations was the direct cause of the acid ceramidase deficiency in the respective patients. In contrast, two known polymorphisms had no effect on acid ceramidase activity. Metabolic labeling studies in fibroblasts of four patients showed that even though acid ceramidase precursor protein was synthesized in these individuals, rapid proteolysis of the mutated, mature acid ceramidase occurred within the lysosome. Hum Mutat 17:199-209, 2001.


📜 SIMILAR VOLUMES


Molecular analysis in spanish patients w
✍ Miguel A. Martín; Juan C. Rubio; Fernando De Bustos; Pilar Del Hoyo; Yolanda Cam 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

The most common mutation in muscle carnitine palmitoyltransferase II (CPT II) deficiency is a missense mutation that replaces a leucine for a serine residue at amino acid position 113 of the CPT II protein (S113L). We performed molecular analysis in a group of 14 Spanish patients with CPT II deficie